5 Results for "

ROS1G2032R

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "ROS1G2032R" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-131003
CAS No.: 1505515-69-4
Purity:  99.78%
Synonyms: DS-6051b; AB-106; IBI-344
Target:  

ROS Kinase

Research Areas:  

Cancer

Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
loading...
    loading...
Cat. No.: HY-152292
CAS No.: 2739829-00-4
Purity:  99.55%
Synonyms: NVL-520; NUV-520
Target:  

ROS Kinase

Research Areas:  

Cancer

Zidesamtinib (NVL-520) is a potent, selective, orally active and brain-penetrant inhibitor of diverse ROS1 fusions and resistance mutations, with IC50s of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and spares TRK inhibition. Zidesamtinib can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-131003A
CAS No.: 1505514-27-1
Synonyms: DS-6051b free base; AB-106 free base; IBI-344 free base
Target:  

ROS Kinase

Research Areas:  

Cancer

Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib free base also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
loading...
    loading...
Cat. No.: HY-157391
Research Areas:  

Cancer

ALK/ROS1-IN-3 (compound C01) is a ROS1 and ALK dual inhibitor with IC50s of 42.3 nM and 49.1 nM for ROS1 G2032R and ALK G1202R, respectively .
loading...
    loading...
Cat. No.: HY-176942
CAS No.: 2644645-39-4
Synonyms: JYP0322
Target:  

ROS Kinase Trk Receptor

Research Areas:  

Cancer

Fudotinib (JYP0322) (ROS1-IN-3) is a potent orally active, selective, and CNS-penetrant ROS1 inhibitor. Fudotinib selectively inhibits human wild-type ROS1 and human ROS1 G2032R with IC50s of 0.37 and 0.3 nM, respectively, showing 6-130-fold selectivity over TRKA, TRKB, and TRKC. Fudotinib inhibits proliferation of ROS1 fusion-expressing cells, and inhibits tumor growth in mouse xenograft models. Fudotinib can be used for the research of non-small cell lung cancer (NSCLC) .
loading...
    loading...